Evidence map›Paper›PMID 29701283›Full record

ArticlePhytotherapy research : PTR2018

Therapeutic effect of Northern Labrador tea extracts for acute myeloid leukemia.

Colin M McGill, Patrick L Tomco, Regina M Ondrasik, Kaitlyn C Belknap, Gaelen K Dwyer, Daniel J Quinlan, Thomas A Kircher, Cheryl P Andam, Timothy J Brown, David F Claxton and 1 more

Open access · greenAbstract read
In one paragraph

Article in Phytotherapy research : PTR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Alaska's Flora as a Treatment for Cancer.International journal of biopharmaceutical sciences · 2024
    Article
  3. Phytochemical Profiling and Biological Activities ofPlants (Basel, Switzerland) · 2024
    Review
  4. Article
  5. The Role of Ceramide and Sphingolipid Metabolism in Cancer Therapeutics.Journal of oncology research and therapy · 2024
    Article
  6. Review
  7. Molecules (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Colin M McGillDepartment of Chemistry, University of Alaska Anchorage, Anchorage, AK, 99508, USA.
Patrick L TomcoDepartment of Chemistry, University of Alaska Anchorage, Anchorage, AK, 99508, USA.
Regina M OndrasikDepartment of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA, 17033, USA.
Kaitlyn C BelknapDepartment of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, 03824, USA.
Gaelen K DwyerDepartment of Chemistry, University of Alaska Anchorage, Anchorage, AK, 99508, USA.
Daniel J QuinlanDepartment of Chemistry, University of Alaska Anchorage, Anchorage, AK, 99508, USA.
Thomas A KircherDepartment of Chemistry, University of Alaska Anchorage, Anchorage, AK, 99508, USA.
Cheryl P AndamDepartment of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, 03824, USA.
Timothy J BrownDepartment of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA, 17033, USA.
David F ClaxtonDepartment of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA, 17033, USA.
Brian M BarthDepartment of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA, 17033, USA.ORCID http://orcid.org/0000-0002-3542-1804
University of Alaska Anchorage · USPenn State Milton S. Hershey Medical Center · USUniversity of New Hampshire · US

Funding

Regulation of Ceramide-Based Therapeutics in Acute Myeloid LeukemiaK22CA190674 · NCI · UNIVERSITY OF NEW HAMPSHIRE · PI BARTH, BRIAN MICHAEL · 2016 to 2018
$485k
NCI NIH HHS K22 CA190674
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is an aggressive hematological malignancy that is one of the more common pediatric malignancies in addition to occurring with high incidence in the aging population. Unfortunately, these patient groups are quite sensitive to toxicity from chemotherapy. Northern Labrador tea, or Rhododendron tomentosum Harmaja (a.k.a. Ledum palustre subsp. decumbens) or "tundra tea," is a noteworthy medicinal plant used by indigenous peoples in Alaska, Canada, and Greenland to treat a diversity of ailments. However, laboratory investigations of Northern Labrador tea, and other Labrador tea family members, as botanical sources for anticancer compounds have been limited. Utilizing an AML cell line in both in vitro and in vivo studies, as well as in vitro studies using primary human AML patient samples, this study demonstrated for the first time that Northern Labrador tea extracts can exert anti-AML activity and that this may be attributed to ursolic acid as a constituent component. Therefore, this medicinal herb holds the potential to serve as a source for further drug discovery efforts to isolate novel anti-AML compounds.

Indexed as

AnimalsCell Line, TumorHumansLedumLeukemia, Myeloid, AcuteMaleMiceMice, Inbred C57BLPlant ExtractsPlants, MedicinalTriterpenesUrsolic AcidPlant ExtractsTriterpenesUrsolic Acidacute myeloid leukemiaNorthern Labrador teaRhododendron tomentosumursolic acid

Identifiers

PMID29701283
PMCPMC7992109
OpenAlexW2799410313

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.